CEL-SCI Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference
September 03 2019 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy company, today announced that Geert Kersten,
Chief Executive Officer, is scheduled to present at the H.C.
Wainwright 21st Annual Global Investor Conference on Tuesday,
September 10th at 11:15 a.m. Eastern Time.
A live webcast of Mr. Kersten’s presentation will be available
in the Investors section of the Company's website at
https://cel-sci.com/new-investor-information/. The webcast will be
available for 90 days following the presentation.
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient's immune system while
it is still intact should provide the greatest possible impact on
survival. Therefore, in the Phase 3 study CEL-SCI treats patients
who are newly diagnosed with advanced primary squamous cell
carcinoma of the head and neck with Multikine first, BEFORE they
receive surgery, radiation and/or chemotherapy. This approach is
unique. Most other cancer immunotherapies are administered only
after conventional therapies have been tried and/or failed.
Multikine (Leukocyte Interleukin, Injection), has received Orphan
Drug designation from the FDA for neoadjuvant therapy in patients
with squamous cell carcinoma (cancer) of the head and neck.
CEL-SCI's Phase 3 study is the largest Phase 3 study in the
world for the treatment of head and neck cancer. Per the study's
protocol, newly diagnosed patients with advanced primary squamous
cell carcinoma of the head and neck are treated with the Multikine
treatment regimen for 3 weeks prior to the Standard of Care (SOC)
which involves surgery, chemotherapy and/or radiation. Multikine is
designed to help the immune system "see" the tumor at a time when
the immune system is still relatively intact and thereby thought to
better able to mount an attack on the tumor. The aim of treatment
with Multikine is to boost the body's immune system prior to SOC.
The Phase 3 study is fully enrolled with 928 patients and the last
patient was treated in September 2016. To prove an overall survival
benefit, the study requires CEL-SCI to wait until 298 events have
occurred among the two main comparator groups.
The Company's experimental LEAPS technology is currently being
developed as a potential therapeutic vaccine for rheumatoid
arthritis and is supported by grants from the National Institutes
of Health. The Company has operations in Vienna, Virginia, and
in/near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Such statements include, but are not limited to, statements about
the terms, expected proceeds, use of proceeds and closing of the
offering. Factors that could cause or contribute to such
differences include, an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to
raise the necessary capital and the risk factors set forth from
time to time in CEL-SCI's filings with the Securities and Exchange
Commission, including but not limited to its report on Form 10-K
for the year ended September 30, 2018. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005144/en/
COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703)
506-1137
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024